Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308278 | 0.86 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL6315055 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL6308020 | 0.78 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL4249530 | 0.76 | ADORA3 (0.56) | MEN1KMT2A | |
| SCHEMBL16675201 | 0.75 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL822363 | 0.70 | KMT2A (0.56) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL821420 | 0.70 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL16284803 | 0.70 | DEGS1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL21652317 | 0.70 | GRM5 (0.69) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL7246382 | 0.69 | KCNK9 (0.62) | NPC1RAB9ASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919339-B2 | ABCA-1 elevating compounds | CV THEAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1341773-A2 | SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002046172-A2 | SUBSTITUTED 1, 3, 5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | NPC1 6/4885RAB9A 2138/4885SMN1; SMN2 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.